Atria Investments Inc increased its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 25.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 22,253 shares of the company's stock after acquiring an additional 4,570 shares during the quarter. Atria Investments Inc's holdings in Prestige Consumer Healthcare were worth $1,738,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. US Bancorp DE raised its holdings in Prestige Consumer Healthcare by 20.3% during the 3rd quarter. US Bancorp DE now owns 3,978 shares of the company's stock valued at $287,000 after acquiring an additional 672 shares during the period. Covestor Ltd raised its stake in shares of Prestige Consumer Healthcare by 95.6% during the 3rd quarter. Covestor Ltd now owns 1,338 shares of the company's stock valued at $96,000 after purchasing an additional 654 shares during the period. Meritage Portfolio Management lifted its holdings in Prestige Consumer Healthcare by 11.0% during the 3rd quarter. Meritage Portfolio Management now owns 11,992 shares of the company's stock worth $865,000 after purchasing an additional 1,193 shares in the last quarter. Aigen Investment Management LP purchased a new stake in Prestige Consumer Healthcare during the 3rd quarter worth about $345,000. Finally, MQS Management LLC bought a new position in Prestige Consumer Healthcare in the 3rd quarter worth about $552,000. 99.95% of the stock is currently owned by institutional investors.
Prestige Consumer Healthcare Price Performance
Shares of Prestige Consumer Healthcare stock traded up $0.94 on Friday, hitting $83.77. 258,095 shares of the company traded hands, compared to its average volume of 333,965. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $90.04. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The company has a market cap of $4.15 billion, a P/E ratio of 19.62, a P/E/G ratio of 2.69 and a beta of 0.46. The firm's 50-day simple moving average is $81.33 and its 200 day simple moving average is $78.16.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.
Analysts Set New Price Targets
PBH has been the topic of a number of recent analyst reports. Sidoti downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target on the stock. in a report on Monday, December 9th. Raymond James raised shares of Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. DA Davidson raised their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a report on Friday, February 7th. StockNews.com lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Monday. Finally, Oppenheimer increased their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, Prestige Consumer Healthcare has an average rating of "Moderate Buy" and an average target price of $92.60.
Read Our Latest Report on PBH
Insiders Place Their Bets
In other news, SVP Mary Beth Fritz sold 1,678 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the sale, the senior vice president now owns 17,157 shares of the company's stock, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.60% of the company's stock.
Prestige Consumer Healthcare Company Profile
(
Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Further Reading
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
